{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Melanotan Ii",
    "short_name": "Melanotan II",
    "aliases": [
      "MT2"
    ],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Classification describes what Melanotan II is and the general domain where it appears."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-19",
      "human_use_note": "Not FDA-approved. Despite lack of regulatory approval, Melanotan II is widely sold as a research chemical and is used by humans for cosmetic tanning and related melanocortin effects. Product purity, dose labeling, and formulation consistency vary substantially in the gray/illicit market, which increases uncertainty and risk."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 5,
      "severity": "moderate",
      "likelihood": "possible",
      "evidence_grade": "unknown",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "Key risks are driven by: (1) unapproved/non-standardized products in real-world use, (2) melanocortin receptor agonism producing systemic effects (e.g., nausea, flushing, blood pressure changes), (3) reported severe adverse events in case literature (e.g., priapism), and (4) concern signals around changing nevi/pigmentation and possible melanoma association in reports. Evidence includes human interventional pharmacology plus observational and case reports; uncertainty remains high.",
      "developmental_systems_of_concern": [
        "melanocortin",
        "hormonal",
        "puberty"
      ],
      "risk_score": 5
    },
    "sections": {
      "overview": [
        {
          "claim_type": "overview",
          "title": "What it is",
          "population_group": "general",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Melanotan II is a synthetic melanocortin peptide designed to activate melanocortin receptors (notably MC1R) to increase melanin production, and it can also affect other melanocortin pathways linked to sexual function and appetite. Human clinical work exists for specific effects, but most real-world tanning use occurs outside regulated medical products, increasing variability and safety uncertainty.",
          "evidence_refs": [
            "E1",
            "E2",
            "E3",
            "E4",
            "E5"
          ]
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "unit": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "min": null,
          "max": null,
          "frequency": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "duration": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
          "population_group": "general",
          "notes": "Descriptive only. Observed in studies; not instructions.",
          "evidence_refs": []
        }
      ],
      "developmental_risk_block": [
        {
          "claim_type": "risk",
          "population_group": "adolescent",
          "confidence": "unknown",
          "evidence_grade": "unknown",
          "text": "Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.",
          "evidence_refs": []
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "skin appearance and texture support",
        "interest in skin remodeling pathways",
        "weight-loss support (commonly discussed)",
        "metabolic health support (anecdotal)",
        "general recovery and resilience interest (anecdotal)",
        "common biohacker curiosity due to community reports",
        "interest in mechanisms suggested by early evidence",
        "used in goal-based stacking discussions (anecdotal)",
        "exploration in wellness communities despite evidence limits"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "source_type": "pubmed",
        "source_id": "E1",
        "url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "unknown",
        "notes": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
      },
      {
        "id": "E2",
        "source_id": "PMID:16412534",
        "source_type": "review",
        "evidence_grade": "human_observational",
        "title": "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.",
        "year": 2006,
        "url": "https://pubmed.ncbi.nlm.nih.gov/16412534/",
        "notes": "Use to bound harms and uncertainty; not endorsement."
      },
      {
        "id": "E3",
        "source_id": "PMID:40210573",
        "source_type": "journal_article",
        "evidence_grade": "human_observational",
        "title": "Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma?",
        "year": 2025,
        "url": "https://pubmed.ncbi.nlm.nih.gov/40210573/",
        "notes": "Adverse-event context only; case-level evidence."
      },
      {
        "id": "E4",
        "source_id": "E4",
        "source_type": "regulatory",
        "evidence_grade": "unknown",
        "title": "Regulatory/health advisory on unapproved melanotan products (public safety communication)",
        "year": 0,
        "url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "notes": "High-level safety framing; not a clinical study."
      },
      {
        "id": "E5",
        "title": "Melanoma in-situ associated with Melanotan II use (case report PDF)",
        "source_type": "case_report",
        "source_id": "scientificliterature.org:Casereports-20-147",
        "evidence_grade": "human_observational",
        "year": 2019,
        "url": "https://scientificliterature.org/Casereports/Casereports-20-147.pdf",
        "notes": "Association signal only (case report); cannot establish causality; useful for uncertainty/risk disclosure."
      }
    ],
    "changelog": [
      {
        "date": "2026-01-19",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for Melanotan II",
        "detail": "Generated from queue ingestion (Phase 6). Requires human-authored, evidence-bounded content.",
        "evidence_refs": []
      },
      {
        "date": "2026-01-19T13:32:56.641931+00:00",
        "change_type": "content_update",
        "summary": "Added conservative evidence scaffold and linked overview refs (no instructions).",
        "detail": "Curation update: section structure standardized; content review pending. No protocols or instructions are provided.",
        "evidence_refs": [
          "E1",
          "E2",
          "E3",
          "E4"
        ]
      },
      {
        "date": "2026-01-19T15:43:16.140262+00:00",
        "change_type": "content_update",
        "summary": "Filled Melanotan II core identity + risk notes and linked conservative evidence refs (no instructions).",
        "detail": "Removed Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon. language from required fields and added a minimal, conservative evidence set (human interventional + observational/case + regulator warning). No protocol or dosing guidance added.",
        "evidence_refs": [
          "E1",
          "E2",
          "E3",
          "E4",
          "E5"
        ]
      },
      {
        "date": "2026-01-19T16:01:39.283793+00:00",
        "change_type": "content_update",
        "summary": "Filled Melanotan II core identity + risk notes and linked conservative evidence refs (no instructions).",
        "detail": "Removed Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon. language from required fields and added a minimal, conservative evidence set (human interventional + observational/case + regulator warning). No protocol or dosing guidance added.",
        "evidence_refs": [
          "E1",
          "E2",
          "E3",
          "E4",
          "E5"
        ]
      },
      {
        "date": "2026-01-19T16:47:16.401818+00:00",
        "change_type": "content_update",
        "summary": "Curation update: section structure standardized; content review pending. No protocols or instructions are provided.",
        "detail": "Auto-filled evidence metadata using NCBI E-utilities (query-based). Best-effort year extraction for non-NCBI pages where applicable. No dosing/protocol instructions added.",
        "evidence_refs": []
      }
    ],
    "meta": {},
    "topics": {
      "primary": [
        "topic_skin_cosmetic"
      ]
    },
    "slug": "melanotan-ii",
    "practical": {
      "schema_version": "practical_block_v1",
      "bottom_line": "Melanotan II is discussed for tanning and melanocortin-related effects, including libido-related discussions in some communities. Real-world risk is driven by unregulated sourcing, unpredictable pigmentation changes, and systemic side effects.",
      "benefits": [
        "Tanning and pigmentation interest in appearance-focused communities",
        "Cosmetic skin tone interest for photos and events",
        "Libido-related interest in some user communities"
      ],
      "side_effects_common": [
        "Nausea",
        "Flushing",
        "Headache",
        "Reduced appetite",
        "Darkening of existing freckles or moles"
      ],
      "side_effects_serious": [
        "Allergic reaction with hives, facial swelling, or trouble breathing",
        "New or changing mole with rapid change in size, shape, or color",
        "Severe dizziness, fainting, or chest pain"
      ],
      "who_should_be_cautious": [
        "Personal history of melanoma or high-risk skin cancer history",
        "Multiple atypical moles or strong family history of melanoma",
        "Pregnancy or breastfeeding",
        "Children and adolescents",
        "People with significant cardiovascular disease"
      ]
    }
  },
  "canonical_name": "Melanotan Ii",
  "interactions": {
    "drug_classes": [],
    "supplement_classes": [],
    "peptides": []
  },
  "practical": {
    "schema_version": "practical_block_v1",
    "bottom_line": "Melanotan II is discussed for tanning and melanocortin-related effects, including libido-related discussions in some communities. Real-world risk is driven by unregulated sourcing, unpredictable pigmentation changes, and systemic side effects.",
    "benefits": [
      "Tanning and pigmentation interest in appearance-focused communities",
      "Cosmetic skin tone interest for photos and events",
      "Libido-related interest in some user communities"
    ],
    "side_effects_common": [
      "Nausea",
      "Flushing",
      "Headache",
      "Reduced appetite",
      "Darkening of existing freckles or moles"
    ],
    "side_effects_serious": [
      "Allergic reaction with hives, facial swelling, or trouble breathing",
      "New or changing mole with rapid change in size, shape, or color",
      "Severe dizziness, fainting, or chest pain"
    ],
    "who_should_be_cautious": [
      "Personal history of melanoma or high-risk skin cancer history",
      "Multiple atypical moles or strong family history of melanoma",
      "Pregnancy or breastfeeding",
      "Children and adolescents",
      "People with significant cardiovascular disease"
    ]
  }
}
